Polivy is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Polivy is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand namePolivy
Authorized genericpolatuzumab vedotin
Regular genericpolatuzumab vedotin
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Polivy?
The original
–
–

Brand nameThe maker’s card

Genentech Oncology Co-pay Assistance Program

Savings card from Genentech

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a treatment

The card takes up to $25,000 a year off your co-pay.

Sign up on polivy.com 

Or call 1-888-249-4918.

In the maker’s words

“With the Genentech Oncology Co-pay Assistance Program, eligible patients with commercial insurance could pay as little as $0 per treatment for POLIVY.”

From the maker’s offer on polivy.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Polivy itself, from the same company, sold without the brand name, and usually for less. For now Polivy is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Polivy is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated:

  • in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater.
  • in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies.

Source: the FDA label for Polivy (Genentech, Inc.), August 24, 2026. Full label on DailyMed 

Good to know